Pathogenesis of paraneoplastic itch has been recognized to be analogous to neuropathic pain involving peripheral and central sensitization, giving heft to the argument underlying the use of neuropathic pain modulators in this setting. The optimal sequencing of these agents is important while adopting a mechanistic approach. This blog post provides an insight into the identifying characteristics, provides a brief overview of aetiopathogenesis and outlines the clinical management of this phenomenon.

The following clinical features may be used to identify an underlying neuropathic phenotype:

1. Burning, tingling, stinging, electric shock like sensations accompanying the itch.
2. Alloknesis – a non-pruritic stimulus such as clothes touching the skin, bed sheets pressing against the skin, gush of air and stroking movement provoking the sensation of itch.
3. Hyperknesis – A mildly pruritic stimulus producing an exaggerated response.
4. Failure to respond to anti-histamines like cetirizine, fexofenadine and chlorpheniramine.
5. Worsening of symptoms at night
6. Relief with neuromodulating agents
7. Descriptors – “it burns and itches at the same time”, “scratching is of no help”.

C-fibre sensitization, spinal cord wind-up phenomenon and failure of descending modulation are recognised contributory factors.

General measures which might be used in treatment include – avoidance of tight fitting clothes and hot baths, use of cotton clothes, use of emollients and moisturizers, avoidance of hot baths and maintaining a cool sleeping environment.

Paroxetine, mirtazapine and gabapentin are agents which have been found to be useful.

Refractoriness to neuropathic modulation might signal the presence of a more generalized, mixed inflammatory – neuropathic phenotype. Typical features, apart from the generalized distribution, include night time predominance, B-type (fever, night sweats and weight loss) symptoms, elevated inflammatory markers, partial response to neuropathic agents and improvement paralleling response to tumor treatment.

While, neuro-modulatory agents might attenuate the central response, tumor related treatment and other agents such as corticosteroids and aprepitant might be required to counteract the inflammatory stimulus, in refractory pruritus.

P.S. Topical Gabapentin has little or no evidence in this setting and might prove to be quite an expense!!

References

Mahmoud, O., Oladipo, O., Mahmoud, R. H., & Yosipovitch, G. (2023). Itch: From the skin to the brain—Peripheral and central neural sensitization in chronic itch. Frontiers in Molecular Neuroscience, 16, Article 1254020. https://doi.org/10.3389/fnmol.2023.1254020

Andersen, H. H., Akiyama, T., Nattkemper, L. A., van Laarhoven, A., & Elberling, J. (2018). Alloknesis and hyperknesis—Mechanisms, assessment methodology, and clinical implications of itch sensitization. Pain, 159(7), 1185–1197. https://doi.org/10.1097/j.pain.0000000000001200

Hachisuka, J., & Ross, S. E. (2018). Itch and neuropathic itch. In G. F. Gebhart (Ed.), Progress in Brain Research (Vol. 239, pp. 175–204). Elsevier. https://doi.org/10.1016/bs.pbr.2018.07.003

Cite as
Arora, R. D. (2026). Conceptual Engineering (CE9) – paraneoplastic pruritus – identifying a neuropathic component perpetuating the scratch-itch-scratch cycle. Zenodo. https://doi.org/10.5281/zenodo.21031277

Disclaimer
Palliative medicine is a relatively young subspecialty whose intellectual and clinical boundaries continue to evolve. In the absence of definitive texts to address contemporary questions, artificial intelligence tools mainly Anthropic (Claude), have been employed to support deeper conceptual exploration, challenge assumptions, and improve clarity of expression. They do not replace critical scholarship, clinical experience, or editorial judgment. Final responsibility for all interpretations, factual accuracy, originality of synthesis, and the quality of the published material rests entirely with the Founder and Editor.